Drotaverinum

General characteristics. Structure:

Active ingredient: 40 mg of Drotaverinum of a hydrochloride.

Excipients: potato starch, lactoses monohydrate (sugar milk), povidone (polyvinylpirrolidone), talc, magnesium stearate.

Spasmolysant (the means reducing a spasm of smooth muscles). The vasodilating, reducing arterial pressure means. Weakens or completely eliminates spasms of smooth muscles of blood vessels and internals. Drug has spasmolytic effect irrespective of the reasons of spasms.

Advantages of Drotaverinum – that they can replace the drugs relaxing muscles which are prohibited at glaucoma or a hyperplasia of a prostate. As for impact on nervous and cardiovascular system, Drotaverinum does not affect them in any way.

Drug works very quickly, literally within 12 minutes it is already possible to feel its action. It effectively and evenly extends on all bodies and systems of an organism. It is processed and removed by kidneys. Drug reduces an intestines peristaltics.

Drotaverinum – an effective remedy of first aid at gripes: renal, bilious, intestinal, besides, drug broadens bilious channels; it is applied at the cholecystitises, cystitis, spasms caused by a peptic ulcer of a stomach and intestines. Helps to cope with a spastic lock, a spastic colitis, a proctitis, painful false desires. Eliminates the disorder of motive function of a stomach caused by increase in a tone; symptoms of a gastroduodenit.

Eliminates spasms of arteries, helps to get rid of pains in a uterus at monthly. Saves from the headache caused by tension of vessels. It is irreplaceable for pregnant women as helps to reduce tension of muscular muscles of a uterus at the raised tone menacing with an abortion.

Pharmacological properties:

Pharmacodynamics. Myotropic spasmolysant, derivative isoquinoline. Inhibits (FDE) IV phosphodiesterase that leads to accumulation of intracellular cyclic adenosinemonophosphate (tsAMF) and as a result to an inactivation of a light chain of a kinase of a myosin therefore there is a relaxation of smooth muscles.

Irrespective of type of a vegetative innervation, Drotaverinum affects unstriated muscles in digestive tract, bile-excreting, urinogenital and vascular systems. In a myocardium and vessels the enzyme hydrolyzing tsAMF is FDE III that explains lack of serious side effects from cardiovascular system (CCC) and not expressed therapeutic action concerning CCC.

Existence of direct influence on smooth muscles allows to use as a spasmolysant in cases when drugs from group of m-holinoblokatorov are contraindicated (closed-angle glaucoma, a prostate hyperplasia).

Pharmacokinetics. At oral administration absorption – high, the semi-absorption period – 12 min. Bioavailability – 100%. It is evenly distributed in fabrics, gets into smooth muscle cells. Time of achievement of the maximum concentration in blood – 2 h. Communication with proteins of plasma – 95-98%. It is generally removed by kidneys, to a lesser extent – with bile. Does not get through a blood-brain barrier.

Indications to use:

• A spasm of unstriated muscles to urine - and bile-excreting bodies (renal colic, a pyelitis, tenesmus, bilious colic, intestinal colic, dyskinesia of biliary tract and a gall bladder on hyperkinetic type, cholecystitis, a postcholecystectomy syndrome).

• A spasm of unstriated muscles of digestive tract (as a rule, as a part of a combination therapy): the pylorospasm, gastroduodenit, a peptic ulcer of a stomach and duodenum, spastic locks, a spastic colitis, a proctitis.

• Tensor headache.

• A dysmenorrhea, the menacing abortion, the menacing premature births, puerperal pains.

• During the carrying out some tool researches, the cholecystography.

Route of administration and doses:

The adult appoint inside 40-80 mg (1-2 tablets) 2-3 times a day. The maximum daily dose – 240 mg.

To children aged from 3 up to 6 years - in a single dose of 20 mg, the maximum daily dose – 120 mg (in 2-3 receptions); aged from 6 up to 12 years one-time – 40 mg, the maximum daily dose – 200 mg; frequency rate of use – 2-5 times a day.

Features of use:

At treatment of a peptic ulcer of a stomach and duodenum apply in combination with other medicines which are usually appointed for treatment of this group of diseases of a gullet, a stomach and a duodenum.

At intake in therapeutic doses, Drotaverinum does not exert impact on ability to drive the car and to perform the works requiring special attention. At emergence of any side effects, the question of driving of transport and work on machines demands individual consideration.

Side effects:

Dizziness, headache, sleeplessness, heart consciousness, lowering of arterial pressure, allergic reactions, nausea, lock, feeling of heat, perspiration.

Interaction with other medicines:

At simultaneous use can weaken protivoparkinsonichesky effect of a levodopa.

Strengthens action of a papaverine, Bendazolum and other spasmolysants (including m-holinoblokatorov), the lowering of arterial pressure caused by tricyclic antidepressants, quinidine and procaineamide.

Reduces spazmogenny activity of morphine.

Phenobarbital increases expressiveness of spasmolytic action of Drotaverinum.

Contraindications:

Hypersensitivity to drug components, the expressed liver and renal failures, heavy heart failure (a syndrome of low cordial emission), the lactation period.

This dosage form is not applied at children 3 years are younger.

Due to the existence in composition of drug of lactose of monohydrate (milk sugar), its reception is contraindicated at an inborn lactose intolerance, a lactose intolerance, glyukozo-galaktozny malabsorption.

With care. Drotaverinum should be applied with care at arterial hypotension, the expressed atherosclerosis of coronary arteries, a prostate hyperplasia, closed-angle glaucoma, during pregnancy.

Overdose:

There are no data on overdose concerning drug.

Storage conditions:

In dry, protected from light and the place, unavailable to children, at a temperature no more than 25 °C. Period of validity 3 years. Not to apply after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

Tablets of 40 mg. On 10 tablets in a blister strip packaging.

1, 2, 3, 4 or 5 blister strip packagings together with the application instruction in a pack from a cardboard.

On 100 tablets in bank of polymeric. Each can together with the application instruction is placed in a pack from a cardboard.